靶向成纤维细胞活化蛋白的镓-68标记异二聚体放射性配体
本研究合成了一种靶向成纤维细胞活化蛋白(FAP)的异二聚体放射性配体BiFAPI,并用镓-68标记。体外实验显示其结合亲和力与FAP2286和FAPI-04相当,但细胞摄取更优、内化快且外排慢;荷瘤小鼠micro-PET/CT中肿瘤摄取显著高于两种单体衍生物,且可被FAP抑制剂阻断。生物分布显示高肿瘤/血比值和快速清除,作者认为其有潜力用于FAP靶向PET显像和癌症诊疗一体化。
要点
- [68Ga]Ga-BiFAPI放射化学纯度>95%,在PBS和血清中稳定性优异。
- BiFAPI结合亲和力与FAP2286和FAPI-04相当,但细胞摄取更高、内化快、外排慢。
- 荷瘤小鼠micro-PET/CT中肿瘤摄取显著高于[68Ga]Ga-FAP2286和[68Ga]Ga-FAPI-04,可被FAP抑制剂阻断。
原文
BACKGROUND: Fibroblast activation protein (FAP) targeting radiotracers have emerged as promising agents for cancer imaging and therapy. Recent advancements have focused on optimizing these agents for better tumor targeting and enhanced theranostic efficacy. In this study, we introduced a novel heterodimeric radioligand labeled with gallium-68, which targets FAP. We aimed to evaluate its in vitro and in vivo performance, comparing its efficacy with monomeric FAPI derivatives. RESULTS: The heterodimeric ligand BiFAPI was synthesized by conjugating a cyclic peptide with a quinoline-based motif via a DOTA chelator. [68 Ga]Ga-BiFAPI demonstrated high radiochemical purity (> 95%) and exceptional stability in physiological conditions, as well as in both PBS and serum. In vitro studies revealed that the binding affinity of BiFAPI was comparable to that of FAP2286 and FAPI-04. Notably, [68 Ga]Ga-BiFAPI exhibited superior cellular uptake, with rapid internalization and slower efflux rates. Micro-PET/CT imaging in tumor-bearing mice demonstrated significantly higher tumor uptake than [68 Ga]Ga-FAP2286 and [68 Ga]Ga-FAPI-04. Co-injection with a FAP inhibitor reduced tumor uptake, confirming the tracer's FAP specificity. In vitro autoradiography, immunohistochemistry, and Western blotting confirmed the correlation between radioactive tracer accumulation and FAP-positive regions. Biodistribution studies revealed high tumor-to-blood ratios and rapid clearance from non-target tissues, further supporting the tracer's favorable pharmacokinetics. CONCLUSION: [68 Ga]Ga-BiFAPI demonstrated superior tumor-targeting properties, higher tumor uptake, and favorable pharmacokinetics compared to [68 Ga]Ga-FAP2286 and [68 Ga]Ga-FAPI-04. Its promising performance in preclinical models positioned it as a potentially valuable agent for FAP-targeted PET imaging and cancer theranostics.
引用
- Xie C, Peng L, Nie H, et al. A heterodimeric radioligand labeled with gallium-68 targeting fibroblast activation protein. EJNMMI Res. 2025. PMID: 40307510. doi:10.1186/s13550-025-01230-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。